SCHEMBL19975427

SCHEMBL19975427

CC(C(=O)C(=O)NCC1CC1)N(C=O)CC1CCN(C(=O)c2ccccc2)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 4/20 0.47
EPHX2 P34913 3/20 0.47
SMN1; SMN2 Q16637 2/20 0.46
ALDH1A1 P00352 2/20 0.43
ACHE P22303 1/20 0.43
KDM4E B2RXH2 1/20 0.42
PKM P14618 1/20 0.42
HDAC3 O15379 1/20 0.42
HDAC4 P56524 1/20 0.42
HDAC1 Q13547 1/20 0.42
HDAC7 Q8WUI4 1/20 0.42
HDAC2 Q92769 1/20 0.42
HDAC10 Q969S8 1/20 0.42
HDAC11 Q96DB2 1/20 0.42
HDAC8 Q9BY41 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
HDAC9 Q9UKV0 1/20 0.42
HDAC5 Q9UQL6 1/20 0.42
CYP3A4 P08684 1/20 0.41
HPGD P15428 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19974893 0.85 BRD4 (0.33) EPHX1EPHX2SMN1; SMN2ACHEKDM4E
SCHEMBL19974880 0.80 ALDH1A1 (0.35) EPHX1EPHX2SMN1; SMN2ALDH1A1KDM4E
SCHEMBL19974790 0.78 SIGMAR1 (0.40) EPHX1SMN1; SMN2ALDH1A1KDM4EHPGD
SCHEMBL21183548 0.78 EPHX2 (0.39) EPHX1EPHX2SMN1; SMN2ALDH1A1KDM4E
SCHEMBL21176247 0.78 KDM4E (0.48) EPHX1SMN1; SMN2ALDH1A1KDM4EPKM
SCHEMBL19975068 0.77 PTGES (0.43) SMN1; SMN2ALDH1A1ACHEKDM4E
SCHEMBL19975075 0.77 USP2 (0.38) EPHX1EPHX2SMN1; SMN2ALDH1A1KDM4E
SCHEMBL19975106 0.77 EPHX1 (0.40) EPHX1EPHX2SMN1; SMN2ALDH1A1TSHR
SCHEMBL19975241 0.77 EPHX1 (0.40) EPHX1EPHX2SMN1; SMN2ALDH1A1TSHR
SCHEMBL19974883 0.75 ALOX15 (0.47) EPHX1EPHX2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220356148-A1 ANTIVIRAL COMPOUNDS HAPLOGEN GMBH (AT) 2022-11-10 US disclosed
US-11091428-B2 Antiviral compounds HAPLOGEN GMBH (AT) 2021-08-17 US disclosed
US-20190225575-A1 ANTIVIRAL COMPOUNDS LUNIS CONSULTING GMBH (AT) 2019-07-25 US disclosed
EP-3512836-A1 ANTIVIRAL COMPOUNDS Haplogen GmbH (AT) 2019-07-24 EP disclosed
WO-2018050631-A1 ANTIVIRAL COMPOUNDS HAPLOGEN GMBH (AT) 2018-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190225575-A1 ANTIVIRAL COMPOUNDS PLA2G1B, PLA2G12A, PLA2G4C EPHX1 372/4885EPHX2 1455/4885SMN1; SMN2 706/4885
US-20220356148-A1 ANTIVIRAL COMPOUNDS PLA2G12A, PLA2G1B, PLA2G4C EPHX1 449/4885EPHX2 1317/4885SMN1; SMN2 1086/4885
US-11091428-B2 Antiviral compounds PLA2G1B, PLA2G12A, PLA2G4C EPHX1 372/4885EPHX2 1455/4885SMN1; SMN2 706/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.